{"id":"sequential-pd-1-antibody","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism of action is based on the principle of immune checkpoint inhibition, where the PD-1 receptor is normally used by cancer cells to evade immune detection. By blocking this interaction, the antibody allows the immune system to recognize and attack cancer cells more effectively.","oneSentence":"Sequential PD-1 antibody works by binding to the PD-1 receptor on T cells, blocking the interaction with its ligands and thereby enhancing the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:56.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT05981703","phase":"PHASE1","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-09-21","conditions":"Advanced Solid Tumor, Solid Tumor","enrollment":217},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT07447570","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-15","conditions":"Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody","enrollment":27},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT04649385","phase":"PHASE1","title":"BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-03-04","conditions":"Advanced Solid Tumor","enrollment":157},{"nctId":"NCT05267626","phase":"PHASE1, PHASE2","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Aulos Bioscience, Inc.","startDate":"2022-04-04","conditions":"Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma","enrollment":159},{"nctId":"NCT06069830","phase":"NA","title":"PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-12-06","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":89},{"nctId":"NCT07005570","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","status":"RECRUITING","sponsor":"Dechang Diao","startDate":"2025-05-01","conditions":"pMMR/MSS Locally Advanced Rectal Cancer","enrollment":86},{"nctId":"NCT07146230","phase":"PHASE2","title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":52},{"nctId":"NCT07286942","phase":"PHASE2","title":"Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-12-18","conditions":"NSCLC, NSCLC (Non-small Cell Lung Cancer)","enrollment":24},{"nctId":"NCT05703971","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2024-05-09","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":62},{"nctId":"NCT04215978","phase":"PHASE1","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-01-30","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":204},{"nctId":"NCT06577194","phase":"PHASE2","title":"A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-05","conditions":"Rectal Cancer, Advanced Solid Tumor","enrollment":35},{"nctId":"NCT07154316","phase":"PHASE2","title":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT05576480","phase":"PHASE2","title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-06","conditions":"Rectal Cancer, Locally Advanced","enrollment":55},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT07053904","phase":"PHASE1","title":"Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors","status":"ENROLLING_BY_INVITATION","sponsor":"PharmaEssentia","startDate":"2025-04-21","conditions":"Advanced Solid Tumors","enrollment":54},{"nctId":"NCT07052448","phase":"","title":"The Efficacy of Sequential RT After Triple Therapy for uHCC","status":"ENROLLING_BY_INVITATION","sponsor":"Fujian Provincial Hospital","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT04638439","phase":"PHASE1","title":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2022-08-17","conditions":"Chronic Hepatitis B Infection, Chronic Hepatitis D Infection","enrollment":20},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07020247","phase":"PHASE3","title":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-19","conditions":"Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy","enrollment":184},{"nctId":"NCT06673693","phase":"PHASE2","title":"Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC","enrollment":24},{"nctId":"NCT05593458","phase":"PHASE3","title":"Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-04-01","conditions":"Locally Advanced Gastric Carcinoma","enrollment":190},{"nctId":"NCT06913218","phase":"PHASE1","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-07-22","conditions":"Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma","enrollment":60},{"nctId":"NCT06872606","phase":"PHASE2","title":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Rectal Adenocarcinoma","enrollment":33},{"nctId":"NCT06867432","phase":"PHASE2","title":"Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT03667716","phase":"PHASE1","title":"COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Compugen Ltd","startDate":"2018-09-06","conditions":"Advanced Cancer, Ovarian Cancer, Breast Cancer","enrollment":121},{"nctId":"NCT06542588","phase":"PHASE2","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-07-19","conditions":"Rectal Cancer","enrollment":29},{"nctId":"NCT03474640","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies","status":"COMPLETED","sponsor":"TopAlliance Biosciences","startDate":"2018-02-21","conditions":"Advanced Malignancies","enrollment":184},{"nctId":"NCT03743766","phase":"PHASE2","title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","status":"COMPLETED","sponsor":"John Kirkwood","startDate":"2019-03-29","conditions":"Melanoma","enrollment":42},{"nctId":"NCT06061276","phase":"NA","title":"bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":40},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06041477","phase":"PHASE3","title":"Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":540},{"nctId":"NCT06070636","phase":"NA","title":"bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":30},{"nctId":"NCT06457477","phase":"NA","title":"Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-06-15","conditions":"Chronic Hepatitis B","enrollment":50},{"nctId":"NCT03874897","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-03-26","conditions":"Advanced Solid Tumor","enrollment":134},{"nctId":"NCT05540145","phase":"","title":"Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-05-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT02858921","phase":"PHASE2","title":"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma","status":"UNKNOWN","sponsor":"Melanoma Institute Australia","startDate":"2017-11-08","conditions":"Melanoma","enrollment":60},{"nctId":"NCT02499835","phase":"PHASE1, PHASE2","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-07-01","conditions":"Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues","enrollment":66},{"nctId":"NCT05859373","phase":"PHASE1, PHASE2","title":"To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06","conditions":"Non-small Cell Lung Cancer","enrollment":78},{"nctId":"NCT05039736","phase":"PHASE2","title":"A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-02-24","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":""},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT04833387","phase":"PHASE2","title":"PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Colorectal Carcinoma","enrollment":30},{"nctId":"NCT05435768","phase":"","title":"PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2022-08-16","conditions":"Metastatic Solid Tumor","enrollment":51},{"nctId":"NCT02684461","phase":"PHASE2","title":"Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-09-13","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03251313","phase":"PHASE1","title":"PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT01940809","phase":"PHASE1","title":"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-28","conditions":"BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma","enrollment":15},{"nctId":"NCT04233840","phase":"PHASE1, PHASE2","title":"P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-02-12","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT05115500","phase":"PHASE2","title":"ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2021-11-01","conditions":"Carcinoma, Solid Tumor","enrollment":55},{"nctId":"NCT02798406","phase":"PHASE2","title":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects","status":"COMPLETED","sponsor":"DNAtrix, Inc.","startDate":"2016-10-06","conditions":"Brain Cancer, Brain Neoplasm, Glioma","enrollment":49},{"nctId":"NCT03852823","phase":"PHASE1","title":"Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-05-23","conditions":"Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma","enrollment":192},{"nctId":"NCT02677155","phase":"PHASE2","title":"Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-01","conditions":"Follicular Lymphoma","enrollment":10},{"nctId":"NCT04714697","phase":"PHASE2","title":"Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2021-03-01","conditions":"Renal Cell Cancer","enrollment":201},{"nctId":"NCT04373083","phase":"PHASE2","title":"Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-11-15","conditions":"Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT04453930","phase":"PHASE2","title":"A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-08","conditions":"Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02452424","phase":"PHASE1, PHASE2","title":"A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2015-07-02","conditions":"Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":78},{"nctId":"NCT03527251","phase":"PHASE1","title":"Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-05-15","conditions":"Non Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sequential immunotherapy"],"phase":"phase_3","status":"active","brandName":"Sequential PD-1 antibody","genericName":"Sequential PD-1 antibody","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sequential PD-1 antibody works by binding to the PD-1 receptor on T cells, blocking the interaction with its ligands and thereby enhancing the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}